Ofatumumab and its role as immunotherapy in chronic lymphocytic leukemia

Haematologica. 2015 Apr;100(4):411-4. doi: 10.3324/haematol.2015.124107.

Authors

Suneet Sandhu¹, Stephen P Mulligan²

Affiliations

¹ Department of Haematology, Royal North Shore Hospital, St Leonards, NSW Kolling Institute, University of Sydney, St Leonards, NSW, Australia.
² Department of Haematology, Royal North Shore Hospital, St Leonards, NSW Kolling Institute, University of Sydney, St Leonards, NSW, Australia [email protected].

No abstract available

Publication types

Editorial
Introductory Journal Article

MeSH terms

Antibodies, Monoclonal / administration & dosage
Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Humanized
Antineoplastic Agents / administration & dosage
Antineoplastic Agents / therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Humans
Immunologic Factors / administration & dosage
Immunologic Factors / therapeutic use*
Immunotherapy
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
Leukemia, Lymphocytic, Chronic, B-Cell / immunology
Leukemia, Lymphocytic, Chronic, B-Cell / pathology

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antineoplastic Agents
Immunologic Factors
ofatumumab